Literature DB >> 7940667

The dimensions of Creutzfeldt-Jakob disease.

L Manuelidis1.   

Abstract

Mesh:

Substances:

Year:  1994        PMID: 7940667     DOI: 10.1046/j.1537-2995.1994.341095026981.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  12 in total

1.  Agent-specific Shadoo responses in transmissible encephalopathies.

Authors:  Kohtaro Miyazawa; Laura Manuelidis
Journal:  J Neuroimmune Pharmacol       Date:  2010-01-30       Impact factor: 4.147

2.  Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent.

Authors:  L Manuelidis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

3.  Creutzfeldt-Jakob disease in Canada. Laboratory Centre for Disease Control.

Authors: 
Journal:  Can Fam Physician       Date:  1996-11       Impact factor: 3.275

Review 4.  Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: integrating science, legal duties and ethical mandates.

Authors:  T Caulfield; J Dossetor; L Boshkov; J Hannon; D Sawyer; G Robertson
Journal:  CMAJ       Date:  1997-11-15       Impact factor: 8.262

5.  Transmissible encephalopathy agents: virulence, geography and clockwork.

Authors:  Laura Manuelidis
Journal:  Virulence       Date:  2010 Mar-Apr       Impact factor: 5.882

6.  Microglial activation varies in different models of Creutzfeldt-Jakob disease.

Authors:  C A Baker; Z Y Lu; I Zaitsev; L Manuelidis
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

7.  Quantitative recovery of scrapie agent with minimal protein from highly infectious cultures.

Authors:  Ru Sun; Ying Liu; He Zhang; Laura Manuelidis
Journal:  Viral Immunol       Date:  2008-09       Impact factor: 2.257

8.  Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: theoretical risk for real people.

Authors:  S M King; H Watson; H Heurter; M Ricketts; S Elsaadany
Journal:  CMAJ       Date:  1998-10-06       Impact factor: 8.262

9.  Viral particles are required for infection in neurodegenerative Creutzfeldt-Jakob disease.

Authors:  L Manuelidis; T Sklaviadis; A Akowitz; W Fritch
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

10.  Microglia from Creutzfeldt-Jakob disease-infected brains are infectious and show specific mRNA activation profiles.

Authors:  Christopher A Baker; Daniel Martin; Laura Manuelidis
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.